Dr. Reuben S. Harris on APOBEC3B as a Possible Treatment Variable in Breast Cancer
APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Reuben S. Harris, PhD, investigator, Howard Hughes Medical Institute, professor, Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, discusses the need for further analysis of APOBEC3B, an anti-viral enzyme, as a possible treatment variable in breast cancer.
APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Harris looked at APOBEC3B expression and stratified data for recurrent disease outcome overtime. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
